Figure 3.
Immune checkpoint inhibition using anti-PD-L1 antibodies in clinical use such as nivolumab and pembrolizumab. In addition, anti-CTLA4 therapy involving ipilimumab has also been considered in PA treatment.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.